Introducing REXULTI® (brexpiprazole): a new PBS-listed antipsychotic for schizophrenia
Por um escritor misterioso
Descrição
October 1st sees the PBS listing of REXULTI, a novel antipsychotic indicated for the treatment of adults with schizophrenia.
Full article: Pharmacokinetics and metabolism of brexpiprazole, a novel serotonin-dopamine activity modulator and its main metabolite in rat, monkey and human
Table 2 from Brexpiprazole (Rexulti): A New Monotherapy for Schizophrenia and Adjunctive Therapy for Major Depressive Disorder.
PDF) Construction and evaluation of a phospholipid-based phase transition in situ gel system for brexpiprazole
Brexpiprazole: A Newly Approved Atypical Antipsychotic Agent
PDF] Brexpiprazole (Rexulti): A New Monotherapy for Schizophrenia and Adjunctive Therapy for Major Depressive Disorder.
Michael Okun on X: Brexpiprazole (Rexulti) approved by FDA for #Alzheimers agitation. Will it find its way to #Parkinsons? Depends on if it makes motor symptoms significantly worse. It works on D2
Rexulti Full Prescribing Information, Dosage & Side Effects
Rexulti: Package Insert
REXULTI® (brexpiprazole) Adjunctive Use in Major Depressive Disorder
1mg REXULTI TABLET, Schizophrenia, Intas Pharmaceuticals
de
por adulto (o preço varia de acordo com o tamanho do grupo)
